Shusuke Okamura

1.2k total citations
34 papers, 783 citations indexed

About

Shusuke Okamura is a scholar working on Hepatology, Surgery and Cancer Research. According to data from OpenAlex, Shusuke Okamura has authored 34 papers receiving a total of 783 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hepatology, 13 papers in Surgery and 9 papers in Cancer Research. Recurrent topics in Shusuke Okamura's work include Hepatocellular Carcinoma Treatment and Prognosis (26 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers) and Cancer, Lipids, and Metabolism (7 papers). Shusuke Okamura is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (26 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers) and Cancer, Lipids, and Metabolism (7 papers). Shusuke Okamura collaborates with scholars based in Japan. Shusuke Okamura's co-authors include Takuji Torimura, Masahito Nakano, Ryoko Kuromatsu, Takashi Niizeki, Shigeo Shimose, Hironori Koga, Hideki Iwamoto, Tomotake Shirono, Manabu Satani and Shuji Sumie and has published in prestigious journals such as Nutrients, Annals of Surgical Oncology and Oncotarget.

In The Last Decade

Shusuke Okamura

34 papers receiving 776 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shusuke Okamura Japan 16 558 219 206 191 179 34 783
Shigeo Shimose Japan 17 641 1.1× 217 1.0× 246 1.2× 214 1.1× 158 0.9× 65 897
Masahito Nakano Japan 19 775 1.4× 281 1.3× 345 1.7× 250 1.3× 225 1.3× 71 1.1k
Tomotake Shirono Japan 15 529 0.9× 169 0.8× 182 0.9× 159 0.8× 103 0.6× 50 704
Ya-Hao Zhou China 15 710 1.3× 258 1.2× 415 2.0× 199 1.0× 226 1.3× 44 931
Brian Shrager United States 8 547 1.0× 339 1.5× 265 1.3× 165 0.9× 213 1.2× 11 904
Manabu Satani Japan 12 317 0.6× 128 0.6× 153 0.7× 87 0.5× 129 0.7× 19 500
Shengjie Jin China 18 403 0.7× 273 1.2× 259 1.3× 183 1.0× 183 1.0× 80 839
Kenya Yamanaka Japan 17 319 0.6× 327 1.5× 146 0.7× 153 0.8× 129 0.7× 42 711
Yong‐Fa Zhang China 17 397 0.7× 170 0.8× 194 0.9× 160 0.8× 174 1.0× 32 654
Stéphane Zalinski France 13 612 1.1× 357 1.6× 534 2.6× 351 1.8× 109 0.6× 20 1.1k

Countries citing papers authored by Shusuke Okamura

Since Specialization
Citations

This map shows the geographic impact of Shusuke Okamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shusuke Okamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shusuke Okamura more than expected).

Fields of papers citing papers by Shusuke Okamura

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shusuke Okamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shusuke Okamura. The network helps show where Shusuke Okamura may publish in the future.

Co-authorship network of co-authors of Shusuke Okamura

This figure shows the co-authorship network connecting the top 25 collaborators of Shusuke Okamura. A scholar is included among the top collaborators of Shusuke Okamura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shusuke Okamura. Shusuke Okamura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shirono, Tomotake, Hideki Iwamoto, Takashi Niizeki, et al.. (2022). Durable complete response is achieved by balloon‐occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatology Communications. 6(9). 2594–2604. 8 indexed citations
2.
Kuromatsu, Ryoko, Tatsuya Ide, Shusuke Okamura, et al.. (2022). Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer. Cancers. 14(9). 2295–2295. 5 indexed citations
3.
Nakano, Masahito, Kazuta Fukumori, Yoichi Yano, et al.. (2021). Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers. 13(21). 5282–5282. 12 indexed citations
4.
5.
Kamachi, Naoki, Masahito Nakano, Shusuke Okamura, et al.. (2021). Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound. Cancer Reports. 5(2). e1471–e1471. 6 indexed citations
6.
Iwamoto, Hideki, Shigeo Shimose, Yu Noda, et al.. (2021). Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers. 13(11). 2786–2786. 39 indexed citations
7.
Shimose, Shigeo, Hideki Iwamoto, Masatoshi Tanaka, et al.. (2021). Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers. 13(1). 160–160. 37 indexed citations
8.
Niizeki, Takashi, Hideki Iwamoto, Tomotake Shirono, et al.. (2021). Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion. Cancers. 13(17). 4450–4450. 15 indexed citations
9.
Shirono, Tomotake, Takashi Niizeki, Hideki Iwamoto, et al.. (2021). Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. Journal of Clinical Medicine. 10(5). 987–987. 4 indexed citations
10.
Suzuki, Hiroyuki, Hideki Iwamoto, Masahito Nakano, et al.. (2021). Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments. Translational Oncology. 14(11). 101201–101201. 4 indexed citations
11.
Nomura, Yoriko, Jun Akiba, Toru Hisaka, et al.. (2021). Laparoscopic left hepatectomy for a patient with intrahepatic cholangiocarcinoma metastasis in the falciform ligament: a case report. BMC Surgery. 21(1). 122–122. 2 indexed citations
12.
Shimose, Shigeo, Hideki Iwamoto, Masatoshi Tanaka, et al.. (2021). Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival. Oncology. 99(12). 756–765. 2 indexed citations
13.
Nakano, Masahito, Ryoko Kuromatsu, Takashi Niizeki, et al.. (2020). Primary Treatment with Molecular‐Targeted Agents for Hepatocellular Carcinoma: A Propensity Score‐matching Analysis. Hepatology Communications. 4(8). 1218–1228. 18 indexed citations
14.
Shimose, Shigeo, Hideki Iwamoto, Takashi Niizeki, et al.. (2020). Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers. 12(7). 1867–1867. 54 indexed citations
15.
Iwamoto, Hideki, Hiroyuki Suzuki, Shigeo Shimose, et al.. (2020). Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events. Cancers. 12(4). 1010–1010. 44 indexed citations
16.
17.
18.
Okamura, Shusuke, Shuji Sumie, Tatsuyuki Tonan, et al.. (2016). Diffusion-weighted magnetic resonance imaging predicts malignant potential in small hepatocellular carcinoma. Digestive and Liver Disease. 48(8). 945–952. 37 indexed citations
19.
Nagamatsu, Hiroaki, Shuji Sumie, Takashi Niizeki, et al.. (2016). Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study. Cancer Chemotherapy and Pharmacology. 77(2). 243–250. 19 indexed citations
20.
Aino, Hajime, Shuji Sumie, Takashi Niizeki, et al.. (2016). The systemic inflammatory response as a prognostic factor for advanced hepatocellular carcinoma with extrahepatic metastasis. Molecular and Clinical Oncology. 5(1). 83–88. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shigeo Shimose Breakdown of academic impact, for papers by Masahito Nakano Breakdown of academic impact, for papers by Tomotake Shirono Breakdown of academic impact, for papers by Ya-Hao Zhou Breakdown of academic impact, for papers by Brian Shrager Breakdown of academic impact, for papers by Manabu Satani Breakdown of academic impact, for papers by Shengjie Jin Breakdown of academic impact, for papers by Kenya Yamanaka Breakdown of academic impact, for papers by Yong‐Fa Zhang Breakdown of academic impact, for papers by Stéphane Zalinski
Rankless by CCL
2026